Switching Australian patients with moderate to severe inflammatory bowel disease from originator infliximab to biosimilar Inflectra: Interim results from a multicenter parallel cohort study

被引：0
|
作者：
Haifer, C. [1 ,2 ]
Srinivasan, A. [3 ,4 ]
Menon, S. [5 ]
An, Y. [9 ]
Picardo, S. [8 ]
Van Langenberg, D.
Begun, J. [8 ,9 ]
Ghaly, S. [1 ]
Thin, L. [6 ,7 ]
机构：
[1] St Vincents Hosp, Melbourne, Vic, Australia
[2] Univ Sydney, Sydney, NSW, Australia
[3] Eastern Hlth, Box Hill, Vic, Australia
[4] Monash Univ, Melbourne, Vic, Australia
[5] Royal Perth Hosp, Perth, WA, Australia
[6] Fiona Stanley Hosp, Murdoch, WA, Australia
[7] Univ Western Australia, Perth, WA, Australia
[8] Mater Hosp, Brisbane, Qld, Australia
[9] Univ Queensland, Brisbane, Qld, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2019年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
217
引用
收藏
页码：155 / 156
页数：2
相关论文
共 50 条
  • [1] Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study
    Haifer, Craig
    Srinivasan, Ashish
    An, Yoon-Kyo
    Picardo, Sherman
    van Langenberg, Daniel
    Menon, Shankar
    Begun, Jakob
    Ghaly, Simon
    Thin, Lena
    MEDICAL JOURNAL OF AUSTRALIA, 2021, 214 (03) : 128 - +
  • [2] Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab
    Srinivasan, Ashish
    Haifer, Craig
    Thin, Lena
    MEDICAL JOURNAL OF AUSTRALIA, 2021, 215 (09) : 435 - 435
  • [3] Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab
    Lim, David
    Bandiera, Rhiannon
    Handsley, Elizabeth
    MEDICAL JOURNAL OF AUSTRALIA, 2021,
  • [4] Switching from originator infliximab to biosimilar versus continuing on originator in inflammatory bowel disease: results from the observational Project NORTH study
    Hellstrom, Per M.
    Gemmen, Eric
    Ward, Heather A.
    Koo, Hyewon
    Faccin, Freddy
    Xue, Zhenyi
    Malmborg, Petter
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2022, 57 (12) : 1435 - 1442
  • [5] Clinical outcomes of switching from originator to biosimilar infliximab in inflammatory bowel disease
    Lin, M. C-P
    Fauzi, M. N. B. M.
    Subramaniam, K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 149 - 150
  • [6] Switching From Originator to Biosimilar Infliximab in Paediatric Inflammatory Bowel Disease Is Feasible and Uneventful
    Gervais, Lisa
    McLean, Luke L.
    Wilson, Michelle L.
    Cameron, Carol
    Curtis, Lee
    Garrick, Vikki
    Armstrong, Kat
    Tayler, Rachel
    Henderson, Paul
    Hansen, Richard
    Chalmers, Iain
    Wilson, David C.
    Russell, Richard K.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2018, 67 (06): : 745 - 748
  • [7] Switching patients with inflammatory bowel disease from originator to biosimilar SB2 infliximab: A single-center Australian longitudinal study
    Llewelyn, J.
    Radford-Smith, G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 123 - 123
  • [8] Mandatory non-medical switching policy from originator to biosimilar infliximab in patients with inflammatory bowel disease in British Columbia: A cohort study
    Fisher, Anat
    Kim, Jason D.
    Dormuth, Colin
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 133 - 133
  • [9] Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
    Bergqvist, Viktoria
    Kadivar, Mohammad
    Molin, Daniel
    Angelison, Leif
    Hammarlund, Per
    Olin, Marie
    Torp, Jorgen
    Grip, Olof
    Nilson, Stefan
    Hertervig, Erik
    Lillienau, Jan
    Marsal, Jan
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2018, 11
  • [10] Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease
    van Hoeve, Karen
    Dreesen, Erwin
    Hoffman, Ilse
    Van Assche, Gert
    Ferrante, Marc
    Gils, Ann
    Vermeire, Severine
    THERAPEUTIC DRUG MONITORING, 2019, 41 (03) : 317 - 324
12345